{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:28:30Z","timestamp":1793312910767,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-CA009679"],"award-info":[{"award-number":["T32-CA009679"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.coph.2025.102604","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:02:21Z","timestamp":1767114141000},"page":"102604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Advancements in targeted therapies for acute myeloid leukemia"],"prefix":"10.1016","volume":"87","author":[{"given":"Matthew P.","family":"Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Barsouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Elghawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2025.102604_sref1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and Histiocytic\/Dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102604_sref2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib3","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102604_bib4","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib6","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol Rev"},{"key":"10.1016\/j.coph.2025.102604_bib7","first-page":"238","article-title":"Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells","volume":"10","author":"Rosnet","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102604_bib8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coph.2025.102604_bib9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.coph.2025.102604_bib10","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib11","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/cncr.25670","article-title":"Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia","volume":"117","author":"Santos","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.coph.2025.102604_bib12","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_sref13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib14","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1182\/blood-2007-07-101238","article-title":"Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin","volume":"110","author":"Barry","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib16","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coph.2025.102604_bib17","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications","volume":"6","author":"D\u00f6hner","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102604_bib18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood-2024-201058","article-title":"10 year Follow-up of CALGB 10603\/Ratify: midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3 mutant acute myeloid leukemia patients aged 18-60 years","volume":"144","author":"Stone","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18632\/oncotarget.27489","article-title":"Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells","volume":"11","author":"Aikawa","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.coph.2025.102604_bib21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2025.102604_sref22","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102604_bib23","first-page":"2024","article-title":"Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial","volume":"110","author":"Schlenk","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102604_bib24","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib25","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation\u2013positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib26","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-Mutated Relapsed\/Refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_sref27","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137685","article-title":"A phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML: final results","volume":"136","author":"Pratz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib29","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102604_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2023-186699","article-title":"Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML","volume":"142","author":"Yilmaz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib32","series-title":"Acute myeloid leukemia (version 3.2024)","year":"2024"},{"key":"10.1016\/j.coph.2025.102604_bib33","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-Internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib34","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2025.102604_sref35","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-Mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djq187","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism","volume":"102","author":"Reitman","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.coph.2025.102604_bib37","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1038\/s41388-021-01968-2","article-title":"Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer","volume":"40","author":"Qiao","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.coph.2025.102604_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.931462","article-title":"The molecular mechanisms of resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Zhuang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib40","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: a Cancer and Leukemia Group B Study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib41","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib42","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib43","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular pathways: isocitrate dehydrogenase mutations in cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102604_bib44","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2010-03-272146","article-title":"Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia","volume":"116","author":"Thol","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib46","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. food and drug administration systematic analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102604_bib47","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1074\/jbc.M112.435495","article-title":"The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization","volume":"288","author":"Ward","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2025.102604_bib48","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-Mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_sref50","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-Mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib52","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-Mutated acute myeloid leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102604_bib53","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102604_sref54","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1200\/JCO.2024.42.16_suppl.6528","article-title":"Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort","volume":"42","author":"Cortes","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib55","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","author":"Watts","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.coph.2025.102604_bib56","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-022-32436-4","article-title":"Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors","volume":"13","author":"Reinbold","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102604_bib57","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib58","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib59","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2018-99-118287","article-title":"Enasidenib is highly active in previously untreated IDH2 mutant AML: early results from the beat AML master trial","volume":"132","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2023010563","article-title":"A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML","volume":"8","author":"Cai","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102604_bib61","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2025.102604_bib62","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102604_bib63","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib64","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood-2021-146507","article-title":"Updated survival and response analyses from a phase 1 study of ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation","volume":"138","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib65","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102604_bib66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib67","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2023-187060","volume":"142","author":"Ozga","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib68","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/OTT.S145971","article-title":"Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy","volume":"11","author":"Castelli","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.coph.2025.102604_bib69","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/onc.2016.315","article-title":"Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development","volume":"36","author":"Tsai","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.coph.2025.102604_bib70","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.molmed.2004.08.005","article-title":"MLL: a histone methyltransferase disrupted in leukemia","volume":"10","author":"Hess","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.coph.2025.102604_bib71","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coph.2025.102604_bib72","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-Associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102604_bib73","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/195209","article-title":"NPM1\/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling","volume":"2011","author":"Lindstr\u00f6m","year":"2011","journal-title":"Biochem Res Int"},{"key":"10.1016\/j.coph.2025.102604_bib74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41408-024-01004-y","article-title":"Regulation of HOX gene expression in AML","volume":"14","author":"Khan","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2025.102604_bib75","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2005-02-0560","article-title":"Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance","volume":"106","author":"Alcalay","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib76","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102604_bib77","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coph.2025.102604_bib78","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102604_sref79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2025.102604_sref80","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102604_bib81","series-title":"2024 european Hematology Association (EHA) Congress","article-title":"Phase 1b study of azacitidine, venetoclax, and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: interim results of dose escalation from the BEATAML consortium","author":"Zeidner","year":"2024"},{"key":"10.1016\/j.coph.2025.102604_bib82","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","article-title":"Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1","volume":"36","author":"Fiskus","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102604_bib83","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2025.102604_sref84","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in relapsed or refractory NPM1-Mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:46:18Z","timestamp":1773992778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":84,"alternative-id":["S1471489225001006"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102604","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in targeted therapies for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102604"}}